利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

479 条记录 (耗时 0.019 秒)

    FXIII DETECTION FOR VERIFYING SERUM SAMPLE AND SAMPLE SIZE AND FOR DETECTING DILUTION
    63.
    发明公开
    FXIII DETECTION FOR VERIFYING SERUM SAMPLE AND SAMPLE SIZE AND FOR DETECTING DILUTION 有权
    FXIII检测血清样本进行核对并-PROBENGRÖSSE和更薄检测

    公开(公告)号：EP1397388A4

    公开(公告)日：2005-04-13

    申请号：EP02726954

    申请日：2002-05-28

    申请人： BIO RAD LABORATORIES

    发明人： BINDER STEVEN R ,  GOODRICH JODI L ,  SAFARIAN ZARA

    IPC分类号： G01N33/53 ,  G01N33/96 ,  C07K16/36 ,  C07K16/00

    CPC分类号： G01N33/96 ,  G01N2333/9108 ,  Y10S435/973

    摘要： Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.

    METHODS FOR REDUCING ADVERSE SIDE EFFECTS ASSOCIATED WITH CELLULAR TRANSPLANTATION
    66.
    发明公开
    METHODS FOR REDUCING ADVERSE SIDE EFFECTS ASSOCIATED WITH CELLULAR TRANSPLANTATION 审中-公开
    VERFAHREN ZUR VERRINGERUNG VONUNERWÜNSCHTENNEBENWIRKUNGEN BEI DER ZELLTRANSPLANTATION

    公开(公告)号：EP1143797A4

    公开(公告)日：2004-12-08

    申请号：EP99966696

    申请日：1999-12-28

    申请人： ALG COMPANY

    发明人： HURWITZ DAVID R ,  CHERINGTON VAN ,  GALANOPOULOS THEOFANIS ,  LEVINE PETER H ,  GREENBERGER JOEL S

    IPC分类号： C12N15/09 ,  A61K35/12 ,  A61K35/28 ,  A61K35/48 ,  A61K38/37 ,  A61K38/48 ,  A61K48/00 ,  A61P7/02 ,  A61P7/04 ,  C07K16/28 ,  C07K16/36 ,  C07K16/40 ,  C12N5/06 ,  C12R1/91 ,  A01N43/04 ,  A01N63/00 ,  A61F2/00 ,  A61K38/00 ,  A61K39/395 ,  C07H21/04 ,  C12N5/00 ,  C12N5/10 ,  C12N15/11

    CPC分类号： C07K16/36 ,  A61K38/37 ,  A61K38/4846 ,  C07K16/40

    摘要： The methods of the present invention are based on the discovery that adverse side effects (such as hemorrhage) can occur upon infusion of cells that express tissue factor. Accordingly, the methods of the invention are aimed at reducing the biological activity of tissue factor (TF) in a patient, and can be carried out by, for example: infusing fewer cells (or infuse the same number of BMSCs over a longer period of time); reducing the expression or activity of TF (within the infused cells specifically) (e.g., by contacting the cells with a TF antagonist in vitro) or within the patient generally (e.g., by administering a TF antagonist to the patient); hampering the interaction of TF with factor VII(a); inhibiting the activity of the TF-factor VII(a) complex once it has formed; or inhibiting the coagulation cascade at any point downstream from formation of the complex (including inhibition of platelet activation).

    摘要翻译： 本发明的方法是基于这样的发现，即在输注表达组织因子的细胞时可能发生不良副作用（例如出血）。 因此，本发明的方法旨在降低患者组织因子（TF）的生物学活性，并且可以通过例如：输注更少的细胞（或在较长时间内注入相同数量的BMSCs） 时间）; 降低TF的表达或活性（例如，通过体外将细胞与TF拮抗剂在体外接触）或患者体内（例如通过向患者施用TF拮抗剂）来抑制TF的表达或活性;阻碍TF的相互作用 与因子VII（a）;一旦形成复合体，就抑制TF-因子VII（a）复合物的活性;或者抑制复合物形成下游任何点的凝血级联（包括抑制血小板活化）。

    FXIII DETECTION FOR VERIFYING SERUM SAMPLE AND SAMPLE SIZE AND FOR DETECTING DILUTION
    70.
    发明公开
    FXIII DETECTION FOR VERIFYING SERUM SAMPLE AND SAMPLE SIZE AND FOR DETECTING DILUTION 有权
    FXIIIA-PROOF进行验证血清样本

    公开(公告)号：EP1397388A1

    公开(公告)日：2004-03-17

    申请号：EP02726954.7

    申请日：2002-05-28

    申请人： BIO-RAD LABORATORIES, INC.

    发明人： BINDER, Steven, R. ,  GOODRICH, Jodi, L. ,  SAFARIAN, Zara

    IPC分类号： C07K16/36 ,  C07K16/00

    CPC分类号： G01N33/96 ,  G01N2333/9108 ,  Y10S435/973

    摘要： Analyses of serum samples for the presence and amount of either of the two subunits of human Factor XIII protein are used as a means of eliminating a significant source of error that arises in the testing of serum and plasma. For serum samples, a negative result of an analysis for the presence of subunit a is a means of verifying that a sample is indeed serum, while a negative or positive result for subunit a serves to distinguish serum (negative) from plasma (positive). A positive result for the presence of subunit b is a means of verifying that the sample is either serum or plasma and not any other biological fluid. A quantitative analysis of subunit b is a means of verifying that the sample is of the intended volume rather than having been reduced in volume due to improper sampling. A quantitative analysis of subunit b is also a means of verifying the dilution of a sample of either serum or plasma.